Open AccessSerum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma
Author(s) -
Ahmed O. Kaseb,
Yinghui Guan,
Betül Gök Yavuz,
Alexander R. Abbas,
Shan Lu,
Elshad Hasanov,
Han Chong Toh,
Wendy Verret,
Yulei Wang
Publication year - 2022
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s369951
Subject(s) - medicine , bevacizumab , atezolizumab , hepatocellular carcinoma , hazard ratio , sorafenib , confidence interval , oncology , gastroenterology , multivariate analysis , proportional hazards model , cancer , chemotherapy , nivolumab , immunotherapy